Literature DB >> 24408089

A subset of CD20(+) MM patients without the t(11;14) are associated with poor prognosis and a link to aberrant expression of Wnt signaling.

Jing Liu1, Zhimin Gu, Ye Yang, Erik Wendlandt, Hongwei Xu.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24408089      PMCID： PMC4449615          DOI： 10.1002/hon.2120

Source DB:  PubMed          Journal:  Hematol Oncol        ISSN： 0278-0232            Impact factor:   5.271


× No keyword cloud information.
  11 in total

1.  Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells.

Authors:  Fenghuang Zhan; Johanna Hardin; Bob Kordsmeier; Klaus Bumm; Mingzhong Zheng; Erming Tian; Ralph Sanderson; Yang Yang; Carla Wilson; Maurizio Zangari; Elias Anaissie; Christopher Morris; Firas Muwalla; Frits van Rhee; Athanasios Fassas; John Crowley; Guido Tricot; Bart Barlogie; John Shaughnessy
Journal:  Blood       Date:  2002-03-01       Impact factor: 22.113

2.  The molecular classification of multiple myeloma.

Authors:  Fenghuang Zhan; Yongsheng Huang; Simona Colla; James P Stewart; Ichiro Hanamura; Sushil Gupta; Joshua Epstein; Shmuel Yaccoby; Jeffrey Sawyer; Bart Burington; Elias Anaissie; Klaus Hollmig; Mauricio Pineda-Roman; Guido Tricot; Frits van Rhee; Ronald Walker; Maurizio Zangari; John Crowley; Bart Barlogie; John D Shaughnessy
Journal:  Blood       Date:  2006-05-25       Impact factor: 22.113

Review 3.  Multiple myeloma.

Authors:  Antonio Palumbo; Kenneth Anderson
Journal:  N Engl J Med       Date:  2011-03-17       Impact factor: 91.245

4.  Wnts induce migration and invasion of myeloma plasma cells.

Authors:  Ya-Wei Qiang; Katie Walsh; Lei Yao; Noemi Kedei; Peter M Blumberg; Jeffrey S Rubin; John Shaughnessy; Stuart Rudikoff
Journal:  Blood       Date:  2005-05-10       Impact factor: 22.113

Review 5.  Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates.

Authors:  David J FitzGerald; Alan S Wayne; Robert J Kreitman; Ira Pastan
Journal:  Cancer Res       Date:  2011-10-15       Impact factor: 12.701

6.  NEK2 induces drug resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancers.

Authors:  Wen Zhou; Ye Yang; Jiliang Xia; He Wang; Mohamed E Salama; Wei Xiong; Hongwei Xu; Shashirekha Shetty; Tiehua Chen; Zhaoyang Zeng; Lei Shi; Maurizio Zangari; Rodney Miles; David Bearss; Guido Tricot; Fenghuang Zhan
Journal:  Cancer Cell       Date:  2013-01-14       Impact factor: 31.743

Review 7.  Antibody-drug conjugates in hematologic malignancies.

Authors:  Lori A Leslie; Anas Younes
Journal:  Am Soc Clin Oncol Educ Book       Date:  2013

8.  Illegitimate WNT signaling promotes proliferation of multiple myeloma cells.

Authors:  Patrick W B Derksen; Esther Tjin; Helen P Meijer; Melanie D Klok; Harold D MacGillavry; Marinus H J van Oers; Henk M Lokhorst; Andries C Bloem; Hans Clevers; Roel Nusse; Ronald van der Neut; Marcel Spaargaren; Steven T Pals
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-05       Impact factor: 11.205

Review 9.  Anti-CD20 monoclonal antibody therapy in multiple myeloma.

Authors:  Prashant Kapoor; Patricia T Greipp; William G Morice; S Vincent Rajkumar; Thomas E Witzig; Philip R Greipp
Journal:  Br J Haematol       Date:  2008-03-03       Impact factor: 6.998

10.  RARα2 expression confers myeloma stem cell features.

Authors:  Ye Yang; Jumei Shi; Giulia Tolomelli; Hongwei Xu; Jiliang Xia; He Wang; Wen Zhou; Yi Zhou; Satyabrata Das; Zhimin Gu; Dana Levasseur; Fenghuang Zhan; Guido Tricot
Journal:  Blood       Date:  2013-07-11       Impact factor: 22.113
View more
  1 in total

1.  Multiple Myeloma and Its Precursor Disease Among Firefighters Exposed to the World Trade Center Disaster.

Authors:  Ola Landgren; Rachel Zeig-Owens; Orsolya Giricz; David Goldfarb; Kaznouri Murata; Katie Thoren; Lakshmi Ramanathan; Malin Hultcrantz; Ahmet Dogan; George Nwankwo; Ulrich Steidl; Kith Pradhan; Charles B Hall; Hillel W Cohen; Nadia Jaber; Theresa Schwartz; Laura Crowley; Michael Crane; Shani Irby; Mayris P Webber; Amit Verma; David J Prezant
Journal:  JAMA Oncol       Date:  2018-06-01       Impact factor: 31.777
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.